Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD20-targeting CAR-T cells with constitutively active gp130
- Development stage
- Preclinical
- Lead developer
- Qihan Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD20-targeting CAR-T cells with constitutively active gp130 (cGP130) is an experimental cellular immunotherapy designed to treat B-cell malignancies and potentially autoimmune diseases. This construct co-expresses a chimeric antigen receptor (CAR) specific for the CD20 antigen alongside a constitutively active form of the gp130 receptor (cGP130), which mimics IL-27 signaling. The inclusion of cGP130 is intended to drive T-cell proliferation and persistence through the JAK-STAT signaling axis in a cell-intrinsic manner, potentially eliminating the requirement for toxic lymphodepleting chemotherapy (e.g., fludarabine/cyclophosphamide) prior to infusion. Preclinical studies in murine and non-human primate (NHP) models have demonstrated enhanced anti-tumor efficacy and robust expansion without uncontrolled growth or systemic toxicity.
- Other names
- cGP130-armored CD20 CAR-T cellscGP-130-armored CD20 CAR-T cellscGP 130-armored CD20 CAR-T cellsIL-27 receptor armored CAR-T cellsIL27 receptor armored CAR-T cellsIL 27 receptor armored CAR-T cells
02
Targets
IL6ST (Interleukin-6 receptor subunit beta)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on CD20-targeting CAR-T cells with constitutively active gp130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD20-targeting CAR-T cells with constitutively active gp130.